Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Even more important. Now $$$ are commuted and changing Hands.em
Wow. Serious bid increase. Yippie!!!!!
9:51 PST: Looks like she's about to blow. L2 looks Fantastic. eom
My prediction for today. High of .0040, close at .003-.0036. Tomorrow we smile. One of 3 things should happen. The seller we have been enduring will:
1 If they are a legitimate (conversion) seller, they will back off and wait for a higher PPS
2 If we have a legitimate short seller, they will cover.
3 If we have an illegitimate naked short seller, we are screwed.
This PR helps tremendously. Wes is a National League Hall of Fame Member, with a strong reputation. CRE is an affliction that attracts attention as inflicts the famous. This will result many investors betting on the stock and it's powerful potential. Wes Chandler is invested officially now. More importantly in my opinion, he has also been working behind the scenes. At least, since 2018. A minimum two years, maybe more. He's created a company that could do wonders for us. I'm excited. Short term, this should move due to broad increasing of awareness in TSOI, resulting in PPS increase.
Looks like it's happening right now. Should be an interesting day/week. I'm so glad I held through the "famine" here the last 10 months.
Looks to me like Mr. Dixon is counting on Wes Chandler and possibly others. Personally I think we will rock and roll in the New Year. Merry Christmas to All. And a prosperous New Year!!
https://www.otcmarkets.com/filing/conv_pdf?id=13734020&guid=XVZvUWxnK7R3G3h
"(3)
"Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
Yes x No o
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
It is likely that there will be significant changes in the Company’s revenues and operating expenses for the period ended September 30, 2018 as compared to the period ended September 30, 2017. However, a reasonable estimate of such changes cannot be made at this time because the financial statements are still being compiled."
https://ih.advfn.com/stock-market/USOTC/brazil-minerals-pk-BMIX/stock-news/81150426/notification-that-quarterly-report-will-be-submitt
Patents Dixon/Ichim
https://patents.justia.com/inventor/timothy-g-dixon
Also, I believe he still holds these shares. Right centsability4me?
https://sec.report/Document/0001078782-19-000023
"Due to the activity in the last quarter of the fiscal year"
"Reason for Delay in Posting Financial Report: State below in reasonable detail why the Annual/Quarterly Report could not be filed within the prescribed time period. Due to the activity in the last quarter of the fiscal year it has taken longer than expected to complete the financials."
https://backend.otcmarkets.com/otcapi/company/financial-report/230983/content
Sounds good to me. Only 2 weeks away.
Yep, owned them both. LOL eom
Hey Maynard, Great to see you are still working the system. Lot of water under our bridge. BMIX looks good to me. GLTU
Sure, because of THIS:
https://ih.advfn.com/stock-market/USOTC/brazil-minerals-inc-BMIX/stock-news/80540756/current-report-filing-8-k
SURPRISE: Can't wait for Sunrise.
When you lie you lose all credibility. Looks like pretty lite volume to me. What say you to what Barchart shows? No response will show a willing liar. "The AS went up 250,000,000 shares a couple days ago.... sort of when all the selling started and the pps began to nose dive.... I do not see this slowing down!!" https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150410138
https://www.barchart.com/stocks/quotes/BMIX/interactive-chart
Okay. Thanks for the clarification and quick reply. Gltu
superbingo
Thank you for the great summation.
Where did you find this:
"In connection with the anticipated closing, $TSOI will pay a fee (the "Fee") of Undisclosed US$ to John Peck in full satisfaction and settlement of certain finder services performed on Tsoi’s behalf. The Fee will be paid through (1) a undisclosed cash payment in the amount of US$ or (2) the issuance of common shares of Tsoi in the aggregate amount of US$1 M plus or minus, priced around at US$0.0035 , representing the closing market price of a TSOI common share on the otcmarket on the trading day."
Do you have a link? Please TIA
I find it very interesting Amit Patel and Jadi Cell exercised their right to convert 19 days after the contract was signed at a gift price of .0016 a share.(strange how the stock tanked, seemingly for no reason, starting in June).They had a year to convert and a clause TSOI could not pre pay any amount of the principle. Sweetheart deal eh? https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80168436/current-report-filing-8-k https://www.sec.gov/Archives/edgar/data/1419051/000107878219000541/f8k061819ex10z11.jpg
Should be good for them and great for shareholders,if Jadi Cell is the real deal. Now, John Peck Jr increases his stake. Also great for shareholders.IMO Buckle up.
The Inspiration For The Formation Of Batu Biologics
“Poet Florica Batu-Ichim was born on April 13, 1945 in Bucharest, the seventh child of a family of Romanians. She married in 1974 with priest and poet Dumitru Ichim and together they settled in Canada where they had 6 children.
She was widely known for her poetry in Romanian and English, authored 10 books, and had a permanent column in Solia—The Herald, the official publication of the Romanian Orthodox Episcopate of America.
When Dr. Thomas Ichim was 12 years old, his mother was diagnosed with late stage leukemia. The night after hearing about his mother’s diagnosis, Tom had a dream that his mother died and decided to dedicate his life to cancer. When he was 19 years old, alongside his sister, Christine Ichim, he founded the Batu Center For Leukemia Research in an effort to develop new treatments for their mother. Research initiated by the Batu Center for Leukemia research was initially funded by the Ichim’s Canadian Cure Campaign, where Christine rollerbladed across Canada to raise awareness for leukemia research.
Florica Batu Ichim passed away in September of 2010 after a 23 year long battle with Leukemia. The book available below is the english translated version of a manuscript she wrote titled “At the Gates of Despair: The Beginnings of Hope”. This compilation of poetry was dedicated to cancer patients and those whose lives are affected by this deadly disease.
Her name lives on in the mission of Batu Biologics, and we hope that this book will provide a shining ray of hope to cancer patients in need of additional support.”
There is a Link to Florica Batu Ichim's moving statement at the bottom of the page.
://www.batubiologics.com/about-us/in-memory-of-florica-batu-ichim/
X] Rule 13d-1(c)
https://www.advfn.com/stock-market/USOTC/TSOI/stock-news/80431970/statement-of-ownership-sc-13g
Rule 13d-1(c) is the “Passive Investor” exemption and provides that holders who (1) have not acquired the securities with any purpose, or with the effect, of changing or influencing the control of the issuer (or in connection with or as a participant in any transaction having that purpose or effect), (2) are not an “Institutional Investor” defined in the “Institutional Investor” exemption and (3) are not directly or indirectly the beneficial owner of 20 percent or more of the class may file a Schedule 13G in lieu of a Schedule 13D. The determination of whether an investor is a “passive investor” is based on the specific facts and circumstances of the investment.
https://www.lexology.com/library/detail.aspx?g=41a16a1b-a159-409c-98ad-39051b7f4753
Looks like we need to change it to 8.
" At present, he has invested in 7 Biotech firms."
https://www.batubiologics.com/achievements/
https://www.batubiologics.com/about-us/
John Peck Jr Batu Biologics
https://www.batubiologics.com/achievements/
https://www.batubiologics.com/achievements/
://www.advfn.com/stock-market/USOTC/TSOI/stock-news/80431970/statement-of-ownership-sc-13g
Now this is getting interesting.
Thank you for this. I had seen it before, but completely forgot about it. I think something major is brewing here. I think the selling the last 45/60 days was manipulation to allow big fish to enter the picture. Just my gut feeling. Could also have been the late Dr. Ma's heirs liquidating her position for probate distribution(just a guess).
Amit Patel and Jadi cell is an interesting arrangement.
After the insider purchases in January, I added a large chunk in late Feb. @ .0078. Only to see it plummet to .001 by June. Glad I held and averaged down. I'm even now, so I think I'll stick around.
centsability4me's DD helped me convince myself to ride it out. I'm glad I did. Thank you cent and others.
Let's keep sharing DD to help ourselves and others. Not too many bashers around, so it's bearable here.
I do. EOM
It's a T Trade listed as a buy.
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/trades
Incredible Penny Stocks: What is a Form T-Trade?
There is much confusion and rumor regarding “T Trades” in the penny stock market. Nasdaq Pink Sheet stocks often close at a certain price and, within 3-10 minutes after the closing bell, will show a large final trade that gets labeled as an “after hours” trade. Simply put, this is an inaccurate description of that trade.
To understand how this trade works, one must understand the role of the market maker. The most frustrating aspect of investing in the pennies, is market maker manipulation of the stock price. Anyone that claims this manipulation doesn’t happen truly does not understand the OTC Market. Market makers are in place to “control” the price of a stock and, theoretically, to ensure that the market reacts properly to supply and demand for a certain stock. Unfortunately, when large sums of money and a lack of regulation are involved, more often than not, there is manipulation that suits the needs of certain investors or the market makers themselves. After all, they are in business to make money as well. If the average investor is purchasing stocks in the OTC Market, that investor is truly at the mercy of the market makers involved in the purchase and sale of that security.
When researching this article, The response from the SEC defined a “Form T Trade” a “trade reporting form used by broker-dealer members of the Financial Industry Regulatory Authority, Inc. (FINRA) to report equity trades executed either in the OTC market or during extended hours trading. Recent amendments to FINRA rules will expand the types of situations in which Form T is to be used, but they are not yet in effect.” The response also recommended contacting FINRA. Notice the first portion of the response. “either in the OTC Market or…” Once again, it is confirmed by the SEC that ”after hours” trades do not exist in the Pinks.
FINRA was much less transparent in their response and essentially spewed the same limited information regarding T Trades that is available on their website. None of which, accurately reflects why these trades occur in the OTC Markets. (http://www.finra.org/web/groups/industry/@ip/@reg/@notice/documents/notices/p123750.pdf)
Trying to decipher the meaning of these trades with the limited information that is available on the subject led down several dark paths. Clearly, the average investor is not meant to understand the concept or its rules. Even more disconcerting is the second part of the SEC message “Recent amendments to FINRA rules will expand the types of situations in which Form T is to be used, but they are not yet in effect.” That means there is even less transparency about this mysterious T Trade.
After months of due diligence, there are a few poorly publicized uses for a T Trade. The most important factor here is that the only requirement of market makers by FINRA is that they must report all trades in a day. They are not required to do so when the actual trade occurs.
To avoid creating “an unbalanced market”, market makers often do not report certain trades during the day to the public and then use a T Trade not to “scare” investors into thinking a market for that stock is going in one direction or the other at the spurring of one large investor.
If a market maker wants to accumulate a large amount of a stock in one trading day, that market maker may actually not report any of the trades that occurred until the trading day has ended so as not to alert the market to the collection. This practice is completely legal under the FINRA rules of the OTC Markets so long as the trade is reported at the end of the day.
To execute a Market on Close” order, a market maker may have an order to purchase the stock at a certain price at the end of the trading day. This is the most unlikely scenario because it needs to be assured that someone selling the stock and someone buying that stock are agreeing upon a price. Simply put, this is more likely with insider buying and selling.
The T Trade that the public sees is nothing more than one or all of the above scenarios. The T Trade reported at the end of the day can be from one market maker or many involved market makers. It can be a single purchase price but is usually an average of all of the previously unreported purchases from that business day.
Penny stocks are an exciting and lucrative business. As most everyone will tell you, it is not for the weak of heart. There is definite money to be made in the OTC Markets and more penny stock millionaires are made every day. But the best way to win the game is to know the rules!
One additional fact surfaced about market makers while researching T Trades. Did you know that market makers are not required to honor their offer price? That is correct, because the OTC market is essentially a “best offer” market. If a buyer meets the asking price for a security, the market maker can, and often does, decide to rescind the offer, not sell the security and adjust the selling price.
Happy Trading.
Penny Stock Emails
Please visit IncrediblePennyStocks.com for more important information and to sign up for our email alerts.https://incrediblepennystocks.wordpress.com/2013/06/25/incredible-penny-stocks-what-is-a-form-t-trade/
""I am honored that a stem cell luminary as powerful as Dr. Amit Patel, the first physician to inject stem cells into the human heart, has entrusted our Company with his potent and promising technology as applied to brain injuries" said Timothy Dixon, President and CEO of TSOI. "We look forward to filing an IND for this technology before year end.""
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80242706/therapeutic-solutions-international-obtains-exclus
https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
Thomas Ichim PhD (TSOI) is listed as a beneficial owner of CELZ, along with Amit Patel, according to this FORM 10-K/A issued by CELZ today.
https://www.otcmarkets.com/filing/html?id=13500388&guid=Ur2xUHCI_Z1O53h
You may be right.
To me it's very interesting who now owns those shares. Amit Patel Jadi Cell.
https://www.otcmarkets.com/filing/html?id=13498273&guid=r4lxUFZZ7PulX3h
https://www.globenewswire.com/news-release/2018/12/10/1664452/0/en/Therapeutic-Solutions-International-Signs-Agreement-for-Licensing-Jadi-Cell-s-Universal-Donor-Adult-Stem-Cell-Product-for-Chronic-Traumatic-Encephalopathy-and-Traumatic-Brain-Injur.html
https://jadicell.com/
https://bciq.biocentury.com/companies/jadi_cell_llc
a month after signing with Jadi, TSOI files it's own patent. https://www.barchart.com/story/stocks/quotes/TSOI/news/207851/therapeutic-solutions-international-continues-to-expand-chronic-traumatic-encephalopathy-intellectual-property-portfolio
Hello, Please anyone with Anthony Goodman's email? TIA
"Yet another area of growth centers on so-called sublinguals, or products delivered under the tongue, like cannabis tinctures, which are becoming more popular among newer cannabis users, largely because the THC dosage is easier to manage. In fact, the cannabis wholesale ordering platform Leaflink has said that cannabis-infused sublingual and tincture products, drops, tablets and strips were the fastest growing cannabis product categories last year."
We may be at the right place at the right time.
This came out yesterday.
Where cannabis investors see the next big wave? In precision dosing
Connie Loizos@cookie / 8 hours ago
Women and seniors are joining the cannabis movement, and that’s presenting new investing opportunities, according to a panel of cannabis investors who we interviewed several days ago at an event organized by the cross-border venture firm DCM.
Specifically, they say, expect to see an uptick in products of all types that make it easier to consume small and controlled amounts of THC, the main psychoactive ingredient in pot.
The trend isn’t so surprising. Anecdotally, women increasingly see cannabis as a potential way to take the edge off without getting plastered, which is not a small concern. Women’s bodies are affected differently by alcohol than are men’s, including because they produce less of a particular enzyme that breaks down alcohol in the body. They’re also working more, drinking more, and developing cirrhosis at a faster rate. According to the Centers for Disease Control and Prevention, the related death rate for women ages 45 to 64 soared a stunning 57 percent between 2000 and 2015, compared with men, whose death rate owing to cirrhosis rose 21 percent over the same period.
Meanwhile, the case for seniors is even more widely understood. Many live with chronic discomfort, including because of arthritis or osteoporosis or sometimes autoimmune diseases that can cause fatigue, joint pain and worse. A growing number is also addicted to OxyContin and other pain killers and looking for a way to lessen their dependence of them. It’s also the case that cannabis isn’t viewed as scandalously as it once was. Former Speaker of the House John Boehner — who is pushing 70 and long opposed he legalization of marijuana — even joined the board of cannabis distributor Acreage Holdings last summer, alongside former Massachusetts Governor Bill Weld. (Age: 73.)
One product promising newcomers a more predictable experience with cannabis is a two-year-old, Woodland, Ca.-based vaporizer company called Indose, whose tagline is “greatness comes with control.” The outfit, which just closed on $3.5 million in funding led by Casa Verde Capital, enables users to adjust how many milligrams of THC they are inhaling from a modest 1 to 2 milligrams, to a more impactful 3 to 4 milligrams, per puff.
Dosist, a Santa Monica, Ca.-based maker of vape pens, similarly appeals to new users. Its pens vibrate when a user has inhaled for three-seconds, a way to help that person calibrate his or her experience. Dosist also markets strains that it formulates in ways that accessible to new users, including selling one strain called simply “Sleep,” and another called “Bliss.”
Yet another area of growth centers on so-called sublinguals, or products delivered under the tongue, like cannabis tinctures, which are becoming more popular among newer cannabis users, largely because the THC dosage is easier to manage. In fact, the cannabis wholesale ordering platform Leaflink has said that cannabis-infused sublingual and tincture products, drops, tablets and strips were the fastest growing cannabis product categories last year.
But perhaps the biggest opportunity going forward may be edibles, which have been around forever but will most certainly begin to look and be marketed differently. DCM, for example, just bet $5 million on a new beverage brand that, beginning this summer, intends to sell flavored THC-infused shots that tell users know exactly how many milligrams they are consuming — along with how they might feel and when.
The company’s target market, as we wrote earlier this week, is women who wouldn’t necessarily smoke a joint but who — thanks to easing regulations, advertising, and smart packaging — are becoming “canna curious,” much like one of the firm’s cofounders, a former consumer packaged goods exec who began experimenting with cannabis herself last year.
And more form factors may be on the horizon. As Karan Wadhera, a managing director at Casa Verde Capital, told us during the panel discussion: “There’s a massive market opportunity out there in many areas” now that the industry has “started to show us that people really do care about actual precise dosing.”
Narbe Alexandrian, the president of the cannabis investment firm Canopy Rivers, fully agreed. He told attendees that “when you look at consumer data, and you look at intenders,” meaning those who currently don’t use cannabis but are open to it, “then look at rejectors,” or people who haven’t used cannabis in the last six months and aren’t likely to consider it, “a lot of rejectors have tried cannabis. But they were turned off by it because they had a weed brownie that hit them too hard, and they never want to touch the substance again.”
The opportunity to sell both camps micro-dosing products is “huge,” said Alexandrian, suggesting that most people welcome more control when offered it. He also hinted that it’s also a wide open field, thanks to the awkward math of many current retailers. As he explained it, it’s often the case today that a store will focus on how many milligrams it’s selling, instead of focusing on the products themselves. “So they’re thinking about selling a 100-milligram beverage for $10 and a 50-milligram beverage for $5” and forcing the customer to figure out how to dilute what they are buying. That will change in the near future, he said.
When she weighed in, panelist and longtime cannabis investor Emily Paxhis echoed the sentiments of both men. More specifically, she said, she has grown “very interested in lower-dose platforms,” especially as women begin seeking out more “moderate dosing” opportunities. She said to think of it as “akin to having a glass of wine or glass of beer, as opposed to, ‘I’m buying straight in for the double martini lunch.'”
Added Paxhis — who cofounded in 2013 the cannabis-focused investment firm Poseidon Asset Management, which hold stakes in a wide variety of companies, including Pax Labs, Juul, an HR startup for the cannabis industry, and a data and analytics company solely focused on it — “There are many ways we can educate the consumer and help them feel more comfortable with [cannabis]. Having these lower-dose products in the market is one great way to do it.”
I don't see anything here about cannabidoil and pterostilbene. Do you know anything about it or have you ever heard the company speak of the combination before? TIA
Ahh, it's a combination, pterostilbene and cannabidiol. This is new to me.
Anyone? Please. Here is an example from another company.
http://neutrisci.com/neutrisci-announces-successful-development-and-positive-results-from-initial-observational-product-trials-with-lexaria-bioscience/
We may have news coming. Cross those fingers.
"cannabidiol"??? Is this something new? I'm unaware of this. TIA
"Look for many new exciting specialty products to come from these facilities
including combination compounds such as pterostilbene and cannabidiol, pterostilbene and alpha-lipoic-acid, pterostilbene and huperzine, all in nanoparticle formulations." https://investorshub.advfn.com/secure/post_reply.aspx?message_id=148186162
I believe this: "The Company has no definite time for the actual delivery of the dividend since this Board Decision will probably require corporate action approval by regulators, and as such no assurances can be given that this approval will be obtained at all. However, the Company is confident in that it will receive this approval and it is the Company’s intention to get all necessary approvals to be able to complete this issue by March 31st, 2019." https://www.otcmarkets.com/stock/MSPC/news/Metrospaces-Declares-a-Dividend-of-76710-IQSTel-Inc-Common-Shares?id=212625
has something to do with this: https://www.otcmarkets.com/filing/html?id=13325498&guid=d5u3UnnGyTGGCth
But that's just me.
Could This Be RMRK??
"$AXXA keeps investors updated: VIP signing is scheduled for tomorrow AM.
Expect the news soon. In the meantime, $AXXA having meetings with Miami based biotech cutting edge research lab that focuses on manufacturing and distribution of a pipeline of CBD based products. $AXXA"
https://twitter.com/exxegroup